Keeping cancer in check
Mendus is a clinical-stage biotechnology company developing cellular immunotherapies for cancer. The company aims to improve disease-free and overall survival in cancers with a high recurrence rate. Its lead product, vididencel, is being developed as maintenance therapy for acute myeloid leukemia (AML) and is about to enter a Phase II clinical trial. As a pre-revenue company, Mendus' risk profile is high, as unfavorable research results can lead to a permanent loss of capital. These risks are offset by significant upside potential if commercialization is successful. Our DCF model suggests upside for stock while relative valuation is in line with Nordic peers. The stock's upside could be realized via a partnering deal or Mendus becoming an acquisition target.
Mendus
Mendus is active in medical technology. The company produces therapeutic vaccines used in the field of oncology. The company mainly drives development in immunotherapy with a focus on the treatment of serious tumors. Examples of diseases that the products are used against include kidney and liver cancer. The largest activity is found within the Nordic market. The company previously went by the name Immunicum and today has its headquarters in Stockholm.
Read more on company page